Cheaper diabetes drug halted by AstraZeneca court win

AstraZeneca won a Federal Court injunction blocking Pharmacor from listing generic versions of diabetes drug Forxiga on Australia's Pharmaceutical Benefits Scheme. Justice Kylie Downes restrained Pharmacor from selling two dapagliflozin products after AstraZeneca sued for patent infringement in December. While Pharmacor admits infringement but claims the patent is invalid, the judge found AstraZeneca's case strong and granted the injunction to preserve its monopoly until the patent expires October 2027. Trial scheduled for August.